What is Leerink Partnrs’ Estimate for VRDN Q1 Earnings?

Viridian Therapeutics, Inc. (NASDAQ:VRDN) – Research analysts at Leerink Partnrs issued their Q1 2025 earnings estimates for shares of Viridian Therapeutics in a research report issued to clients and investors on Monday, January 27th. Leerink Partnrs analyst T. Smith expects that the company will earn ($0.81) per share for the quarter. The consensus estimate for Viridian Therapeutics’ current full-year earnings is ($4.03) per share. Leerink Partnrs also issued estimates for Viridian Therapeutics’ Q2 2025 earnings at ($0.85) EPS, Q3 2025 earnings at ($0.88) EPS, Q4 2025 earnings at ($1.20) EPS, FY2025 earnings at ($3.74) EPS, FY2026 earnings at ($2.95) EPS, FY2027 earnings at ($1.36) EPS and FY2028 earnings at $1.34 EPS.

Viridian Therapeutics (NASDAQ:VRDN) last announced its earnings results on Tuesday, November 12th. The company reported ($1.15) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.11) by ($0.04). Viridian Therapeutics had a negative return on equity of 70.12% and a negative net margin of 85,127.16%. The company had revenue of $0.09 million for the quarter, compared to the consensus estimate of $0.08 million.

A number of other research firms have also recently issued reports on VRDN. TD Cowen initiated coverage on shares of Viridian Therapeutics in a report on Monday, November 25th. They set a “buy” rating for the company. HC Wainwright reiterated a “buy” rating and issued a $34.00 target price on shares of Viridian Therapeutics in a research note on Monday, December 16th. Royal Bank of Canada lifted their price objective on Viridian Therapeutics from $44.00 to $47.00 and gave the stock an “outperform” rating in a report on Tuesday, December 17th. Needham & Company LLC reaffirmed a “buy” rating and set a $38.00 price objective on shares of Viridian Therapeutics in a report on Tuesday, January 7th. Finally, Wells Fargo & Company reiterated an “equal weight” rating and set a $27.00 target price (down from $37.00) on shares of Viridian Therapeutics in a research report on Thursday, December 19th. Three research analysts have rated the stock with a hold rating and nine have given a buy rating to the stock. According to MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $35.70.

Viridian Therapeutics Price Performance

NASDAQ VRDN opened at $19.43 on Wednesday. Viridian Therapeutics has a 1 year low of $11.40 and a 1 year high of $27.20. The company has a fifty day simple moving average of $19.42 and a 200 day simple moving average of $19.40. The company has a current ratio of 18.55, a quick ratio of 18.55 and a debt-to-equity ratio of 0.04. The company has a market cap of $1.54 billion, a P/E ratio of -4.51 and a beta of 1.13.

Hedge Funds Weigh In On Viridian Therapeutics

Several large investors have recently bought and sold shares of VRDN. FMR LLC raised its stake in Viridian Therapeutics by 16.8% during the 3rd quarter. FMR LLC now owns 11,183,478 shares of the company’s stock worth $254,424,000 after buying an additional 1,610,130 shares during the period. Novo Holdings A S grew its position in shares of Viridian Therapeutics by 19.3% in the 3rd quarter. Novo Holdings A S now owns 2,385,000 shares of the company’s stock valued at $54,259,000 after purchasing an additional 385,000 shares during the period. Geode Capital Management LLC boosted its holdings in shares of Viridian Therapeutics by 5.8% in the third quarter. Geode Capital Management LLC now owns 1,493,311 shares of the company’s stock valued at $33,979,000 after buying an additional 81,951 shares during the period. Great Point Partners LLC increased its holdings in Viridian Therapeutics by 50.0% during the 3rd quarter. Great Point Partners LLC now owns 750,000 shares of the company’s stock worth $17,062,000 after purchasing an additional 250,000 shares in the last quarter. Finally, Walleye Capital LLC grew its stake in shares of Viridian Therapeutics by 30.1% during the 3rd quarter. Walleye Capital LLC now owns 560,007 shares of the company’s stock worth $12,740,000 after acquiring an additional 129,411 shares in the last quarter.

About Viridian Therapeutics

Viridian Therapeutics, Inc, a biotechnology company, discover and develops treatments for serious and rare diseases. The company's product pipeline includes VRDN-001, a monoclonal antibody targeting insulin-like growth factor-1 receptor that is in Phase 3 clinical trial for the treatment of thyroid eye disease (TED); and VRDN-003, a next generation IGF-1R humanized monoclonal antibodies targeting IGF-1R and incorporating half-life extension technology for the treatment of TED.